promising treatment options emerging for higher-risk mds & the value of clinical trials
Published 1 year ago • 209 plays • Length 3:31Download video MP4
Download video MP3
Similar videos
-
1:02
emerging treatment options for lower- and higher-risk mds and ongoing trials
-
3:08
the treatment protocol for higher risk mds
-
4:16
pre-mds states: identifying patients at risk and using modern tools to improve prognosis
-
2:06
outcomes & promising treatment options following hma failure in patients with hr-mds
-
1:04
the current standard of care for mds-related cytopenias and how treatment strategies may evolve
-
1:19
the promise of precision medicine in mds
-
2:16
current and future treatment approaches for hr-mds
-
1:18
standardizing mrd techniques after fda approval as a surrogate endpoint in myeloma trials
-
3:43
mrd-guided treatment cessation in multiple myeloma
-
45:36
panel discussion | marketing 2.0 conference
-
13:39
key highlights in mds: treating lower-risk & higher-risk disease, trial updates, and more
-
3:17
pre-mds states: novel therapeutic approaches, and determining appropriate trial endpoints
-
2:33
what can artificial intelligence bring to the diagnosis and management of mds?
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
2:15
decentralized clinical trials to improve patient access
-
2:31
emerging treatment options for patients with esa-refractory mds: luspatercept & imetelstat
-
2:18
treating patients with advanced-stage hl in the frontline and relapsed settings in 2024
-
0:47
overview of the phase iii enhance trial schema
-
5:43
pre- and post-allohsct treatment in mds
-
1:17
exciting novel treatments being developed for mds
-
2:48
the promise of pyruvate kinase activators, such as mitapivat, for treating scd and thalassemia
-
1:30
strategies for mitigating the negative impact scd has on growth and development